Pharmacovigilance Automation

News
Article
Pharmaceutical TechnologyPharmaceutical Technology Quality and Regulatory Sourcebook March 2023
Volume 2023 eBook
Issue 2
Pages: 8-11

Organizations can better understand the maturity of AI-driven automation technology across their organization’s IT landscape through effective pharmacovigilance.



putilov_denis - Stock.adobe.com

putilov_denis - Stock.adobe.com

A safety surveillance strategy is a requirement for pharmaceutical companies to monitor product safety in the post-marketing environment, as well as to keep physicians informed on product risks and how to prescribe appropriately. This is usually seen as a labor-intensive cost center that often overburdens teams with work, making it difficult to retain talent. As the industry becomes more cost-conscious and is handling more real-world data sources than ever, companies are seeking ways to improve the efficiency and effectiveness of their pharmacovigilance (PV) activities. Automation offers the solution for organizations prepared to embrace it and to do the hard work required to support digital transformation.

Why automation is vital in pharmacovigilance

Many reasons exist to support the adoption of automation in drug safety surveillance. Using artificial intelligence (AI) in safety surveillance can automate many aspects of the process, including non-electronic data collection, processing of inbound data, and triaging data according to its source. With these applications, companies can increase productivity, lower their technology costs, and reduce their reliance on manual labor.

Read this article in the Quality and Regulatory Sourcebook 2023

About the author

Updesh Dosanjh is a practice leader for technology solutions at IQVIA.

Article details

Pharmaceutical Technology
eBook: Quality and Regulatory

March 2023
Pages: 8-11

Citation

When referring to this article, please cite it as U. Dosanjh, "Pharmacovigilance Automation," Pharmaceutical Technology's Quality and Regulatory eBook (March 2023).

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content